Blood test can quickly match advanced breast cancer patients to targeted treatments
A blood test can help identify rare mutations in advanced breast cancer, which may enable patients to access effective treatments more quickly in the future, Cancer Research UK scientists have found.*
As part of the plasmaMATCH clinical trial**, funded by Stand Up To Cancer, a joint fundraising campaign from Cancer Research UK and Channel 4, the researchers were able to detect mutations in the DNA from the tumours, which had been shed into the bloodstream.
They found specific weaknesses in the breast cancer DNA that could be targeted with drugs, suggesting that this blood test could be a better way of guiding treatment than standard tissue biopsies, which can be painful and take longer to analyse. Their results were presented at the 2019 San Antonio Breast Cancer Symposium today (Thursday).
The team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, analysed the blood from around 1,000 women with breast cancer that had returned after treatment, or had spread to another part of the body.
They wanted to explore if taking a liquid biopsy, where traces of tumour DNA circulating in the blood can be detected, was a quicker and easier alternative to traditional tumour testing.
Breast cancer is the most common cancer in the UK, with around 55,200 new cases every year,*** and women who are diagnosed later, or whose cancer has come back after treatment have limited treatment options. For example, when the disease is diagnosed at the latest stage, only 1 in 4 (26%) people will survive their cancer for five years or more.****
A small group of breast cancers that have acquired specific mutations, or genetic defects, may be directly targeted with new drugs that are currently undergoing testing in clinical trials. However, these defects are rare, so it’s important to identify the patients who could benefit most.
Currently, these defects are identified by taking out a piece of the tumour using a biopsy or during surgery, a process that is invasive and comparatively slower. These defects can also change after treatment or when cancer spreads, and in advanced cancer, it isn’t always possible to take further biopsies where cancer has spread. So, doctors may be working with an outdated picture.
This new study looked at whether a blood test could detect three targetable defects in genes called HER2, ESR1 and AKT1, which are known to drive breast cancer.
A total of 142 women with these detectable mutations were given experimental targeted therapies against the specific characteristics of their cancer. Those treatments that have shown initial promise will be tested further in larger clinical trials.*****
To validate their findings, the researchers also checked tissue samples from the patients and confirmed that the liquid biopsy had correctly identified the presence or absence of the mutations in over 95% of cases.
This suggests that the blood test could be a robust way of identifying rare subtypes of breast cancer and could replace the more invasive methods of analysing breast tumours.
Professor Nicholas Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden, said: “The choice of targeted treatment we give to patients is usually based on the mutations found in the original breast tumour. But their cancer can have different mutations after it has moved to other parts of the body.
“We have now confirmed that blood tests can quickly give us a bigger picture of the mutations are present within multiple tumours throughout the body, getting the results back to patients accurately and faster than we could before. This is a huge step in terms of making decisions in the clinic, particularly for those women with advanced breast cancer who could quickly be put on new targeted treatments matched to their cancer if it evolves to become drug resistant.”
The researchers believe the blood tests are now reliable enough to be used routinely by doctors, once they have passed regulatory approval. And for the targeted drugs still in development, the next step is to carry out larger clinical trials to assess whether they are better than existing treatments.
Professor Carlos Caldas, senior group leader at the Cancer Research UK Cambridge Institute, said: “This work builds on increasing evidence in favour of liquid biopsies. It’s another step in the right direction and could mean a lot to people with advanced breast cancer, because it can identify those who may benefit from new targeted treatment after other options have stopped working.
“But liquid biopsies are also showing promise beyond guiding treatment choices. It’s relatively easy to take a blood sample, which means the test could be used to monitor how cancer responds throughout a course of treatment, or it may be able to detect the early signs of treatment resistance.”
Dr Emily Farthing, senior research information manager for Stand Up To Cancer, said: “It’s exciting to see that blood tests have real potential to help speed up access to effective treatment for people with advanced breast cancer. Stand Up To Cancer funds translational research like the plasmaMATCH trial, which transforms discoveries in the labs into new tests and treatments that will make a real difference for people with cancer. More than £62 million has been raised in the UK to date, which has funded over 50 clinical trials, so we look forward to seeing more breakthroughs in the future.”
For media enquiries contact the Cancer Research UK press office on 020 3469 8300 or, out of hours, on 07050 264 059.
Notes to Editor
* GS3-06. Turner, N. et al. (2019) Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). San Antonio Breast Cancer Symposium.
GS3-07. Kingston, B. et al. (2019) The genomic landscape of breast cancer based on ctDNA analysis: data from the plasmaMATCH trial. San Antonio Breast Cancer Symposium.
** The plasmaMATCH trial was sponsored by the ICR and The Royal Marsden, and coordinated by the Clinical Trials and Statistics Unit at the ICR. Further information on the trial can be found here: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-using-a-blood-test-to-find-certain-gene-changes-and-decide-treatment-for-advanced-breast
*** Based on the annual average number of new cases of breast cancer (ICD10 C50) in females in the UK between 2014 and 2016.
**** Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.
***** Treatments given to the women in the trial are not yet approved for general use. Patients were sorted into four treatment groups according to which mutations were detected: HER2, ESR1 and AKT1, and women with the AKT1 mutation were further separated according to whether their breast cancer reacted to oestrogen. Five out of 20 women with the HER2 mutation and three out of 18 women with the AKT1 mutation responded to neratinib with or without fulvestrant or capivasertib plus fulvestrant, respectively. Results for further 3 patients with AKT1 mutation are not yet available.